ReviewAAPS PharmSciTech2026
Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by keratinocyte hyperproliferation, dysregulated immune signaling and systemic comorbidities, affecting nearly 2-3% of the global population. Although conventional therapies have improved disease management, they remain limited by poor drug penetration, systemic toxicity, adverse effects, high costs and relapse after discontinuation. The distinctive pathophysiology of psoriatic skin, with its thickened stratum corneum and aberrant immune microenvironment, poses persistent challenges to achieving targeted, sustained drug delivery. To address these limitations, emerging drug delivery systems and devices are being engineered to optimize therapeutic outcomes. Nanocarrier-based platforms are enabling enhanced drug localization, improved bioavailability and modulation of key inflammatory pathways. In parallel, microneedle-assisted delivery, hydrogel scaffolds and nanofiber matrices are establishing themselves as versatile technologies for localized, sustained and patient-friendly administration. Furthermore, stimuli-responsive and bio-inspired systems, incorporating plant-derived bioactives or extracellular vesicles, are advancing the paradigm of personalized and precision medicine in dermatology. This review critically evaluates recent progress in advanced therapeutics, nanotechnology-driven platforms and bioengineered systems for psoriasis therapy, with emphasis on their mechanisms, drug targeting, translational potential and future integration into clinical practice. Additionally, this review provides insight into how advanced delivery systems may redefine the future landscape of psoriasis management.
Indexed as
Identifiers
41807739What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.